SSG
LXRX icon

Summit Securities Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Summit Securities Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2
Closed – – 499
2013
Q2 		$0 Buy
+2
New +$30 ﹤0.01% 606

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Summit Securities Group's LXRX Position: Q3 2013 in Review

Summit Securities Group sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2013, closing a stake of 2 shares.

Summit Securities Group first reported a position in LXRX in Q2 2013 and held it in 1 quarter. The position peaked at $0 in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

  • Summit Securities Group reported no remaining Lexicon Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 2 Lexicon Pharmaceuticals shares in Q3 2013.
  • Summit Securities Group first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's Lexicon Pharmaceuticals position peaked at $0 in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.